• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Kura Oncology Inc.

    6/4/26 5:25:23 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KURA alert in real time by email
    S-8 1 kura-20260604.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 4, 2026

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

    KURA ONCOLOGY, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

     

    Delaware

    61-1547851

    (State or other jurisdiction of
    incorporation or organization)

    (I.R.S. Employer
    Identification No.)

     

     

    4930 Directors Place, Suite 500, San Diego, CA

    92121

    (Address of Principal Executive Offices)

    (Zip Code)

     

    Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan

    Kura Oncology, Inc. Amended and Restated 2015 Employee Stock Purchase Plan

    (Full titles of the plans)

    Troy E. Wilson, Ph.D., J.D.

    President and Chief Executive Officer

    Kura Oncology, Inc.

    4930 Directors Place, Suite 500

    San Diego, California 92121

    (858) 500-8800

    (Name, address, and telephone number, including area code, of agent for service)

     

    Copies to:

    Charles J. Bair, Esq.

    Cooley LLP

    10265 Science Center Drive

    San Diego, California 92121

    (858) 550-6000

    Teresa Bair

    Chief Legal Officer and Secretary

    Kura Oncology, Inc.

    4930 Directors Place, Suite 500

    San Diego, California 92121

    (858) 500-8800

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer

    ☐

     

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

     

    Smaller reporting company

    ☒

     

     

     

     

     

     

     

     

     

     

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    REGISTRATION OF ADDITIONAL SECURITIES

    Kura Oncology, Inc. (the “Registrant”) has prepared this Registration Statement on Form S-8 (this “Registration Statement”) in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended, to register (i) 6,500,000 additional shares of the Registrant’s Common Stock (“Common Stock”) issuable under the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan (the “2014 Plan”), pursuant to an increase in the number of shares of Common Stock reserved for issuance under the 2014 Plan, and (ii) 2,500,000 additional shares of Common Stock issuable under the Kura Oncology, Inc. Amended and Restated 2015 Employee Stock Purchase Plan (the “2015 ESPP” and, together with the 2014 Plan, the “Plans”), pursuant to an increase in the number of shares of Common Stock reserved for issuance under the 2015 ESPP.

    INCORPORATION OF DOCUMENTS BY REFERENCE

    This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plans is effective.

    The Registrant previously registered shares of its Common Stock for issuance under the Plans under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on April 17, 2015 (File No. 333-203504), March 17, 2016 (File No. 333-210260), March 14, 2017 (File No. 333-216683), March 12, 2018 (File No. 333-223591), March 5, 2019 (File No. 333-230075), February 25, 2020 (File No. 333-236621), February 24, 2021 (File No. 333-253441), February 24, 2022 (File No. 333-263000), February 24, 2023 (File No. 333-269974), June 2, 2023 (File No. 333-272389), June 7, 2024 (File No. 333-280050) and June 6, 2025 (File No. 333-287866). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

    Item 8. Exhibits.

    Exhibit
    Number

    Description

    4.1

    Amended and Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 of the Registrant’s Form 8-K filed on June 14, 2017).

     

     

     

    4.2

    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 99.1 of the Registrant’s Form 8-K filed on January 29, 2026).

     

     

     

    4.3

    Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 of the Registrant’s Form 8-K filed on March 12, 2015, containing items 1.01, 2.01, 3.02, 4.01, 5.01, 5.02, 5.03, 5.06 and 9.01).

     

    5.1

    Opinion of Cooley LLP.*

     

     

    23.1

    Consent of Independent Registered Public Accounting Firm.*

     

     

     

    23.2

    Consent of Cooley LLP. Reference is made to Exhibit 5.1.*

     

    24.1

    Power of Attorney. Reference is made to the signature page hereto.*

     

    99.1

    Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan and Forms of Stock Option Agreement, Notice of Exercise and Stock Option Grant Notice thereunder (incorporated by reference to Exhibit 99.1 of the Registrant’s Form 8-K filed on June 4, 2026).

     

     

     

    99.2

     

    Form of Restricted Stock Purchase Agreement and Restricted Stock Purchase Award Notice under the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 of the Registrant’s Form 8-K filed on March 12, 2015, containing items 1.01, 2.01, 3.02, 4.01, 5.01, 5.02, 5.03, 5.06 and 9.01).

     

     

     

    99.3

     

    Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.22 of the Registrant’s Form 10-K filed on February 23, 2023).

     

     

     

    99.4

     

    Kura Oncology, Inc. Amended and Restated 2015 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.2 of the Registrant’s Form 8-K filed on June 4, 2026).

     

     

     

    107

     

    Filing Fee Table*

     

    * Filed herewith

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on June 4, 2026.

     

    Kura Oncology, Inc.

    By:

    /s/ Troy E. Wilson, Ph.D., J.D.

    Troy E. Wilson, Ph.D., J.D.

    President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Troy E. Wilson, Ph.D., J.D. and Thomas Doyle, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature

    Title

    Date

     

     

    /s/ Troy E. Wilson, Ph.D., J.D.

    President, Chief Executive Officer and

    Chairman of the Board of Directors

    June 4, 2026

    Troy E. Wilson, Ph.D., J.D.

    (Principal Executive and Financial Officer)

     

     

     

    /s/ Thomas Doyle

    Senior Vice President, Finance & Accounting

    June 4, 2026

    Thomas Doyle

    (Principal Accounting Officer)

     

     

     

    /s/ Helen Collins, M.D.

    Director

    June 4, 2026

    Helen Collins, M.D.

     

     

     

     

    /s/ Faheem Hasnain

    Director

    June 4, 2026

    Faheem Hasnain

     

     

     

     

    /s/ Thomas Malley

    Director

    June 4, 2026

    Thomas Malley

     

     

     

     

     

     

     

    /s/ Diane Parks

     

    Director

    June 4, 2026

    Diane Parks

     

     

     

     

     

     

     

     

    /s/ Carol Schafer

    Director

    June 4, 2026

    Carol Schafer

     

     

     

     

     

     

     

    /s/ Mary Szela

     

    Director

     

    June 4, 2026

    Mary Szela

     

     

     

     

     

     

     

     

     

    /s/ Michael Vasconcelles, M.D.

     

    Director

     

    June 4, 2026

    Michael Vasconcelles, M.D.

     

     

     

     

     

     

     

     

     

     

     


    Get the next $KURA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KURA

    DatePrice TargetRatingAnalyst
    4/14/2026$23.00Buy
    Lake Street
    9/4/2025Neutral
    Guggenheim
    2/6/2025Buy → Neutral
    BTIG Research
    10/24/2024$27.00Buy
    UBS
    10/14/2024$26.00 → $19.00Buy → Hold
    Stifel
    12/22/2023$26.00Buy
    Mizuho
    8/11/2023$31.00Buy
    BofA Securities
    7/27/2023$10.50Sector Perform
    Scotiabank
    More analyst ratings

    $KURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

    – Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients – – Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients – – Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors – – New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings – – First planned platform combination, darlifarnib + da

    6/3/26 6:53:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

    – 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responders with no prior venetoclax exposure; median CRc duration was 9.2 months – – Median OS not reached after median follow up of 10.7 months in patients with no prior venetoclax exposure – – Combination was well tolerated, with low rates of differentiation syndrome and QTc prolongation observed – SAN DIEGO and TOKYO, June 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA, "Kura")) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today announced the publication in Blood of updated resul

    6/2/26 8:32:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

    – Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib's potential as a precision combination agent across targeted therapies – – Clear clinical activity in KRASi-experienced patients and manageable safety profile – – Virtual investor event on June 3, 2026, at 12:15 p.m. PT / 3:15 p.m. ET – SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today reported compelling first-in-human data fro

    5/26/26 6:02:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Parks Diane L.

    4 - Kura Oncology, Inc. (0001422143) (Issuer)

    6/4/26 6:30:15 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Collins Helen Louise

    4 - Kura Oncology, Inc. (0001422143) (Issuer)

    6/4/26 6:30:10 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hasnain Faheem

    4 - Kura Oncology, Inc. (0001422143) (Issuer)

    6/4/26 6:30:12 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Kura Oncology with a new price target

    Lake Street initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $23.00

    4/14/26 8:04:53 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Kura Oncology

    Guggenheim initiated coverage of Kura Oncology with a rating of Neutral

    9/4/25 9:01:23 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology downgraded by BTIG Research

    BTIG Research downgraded Kura Oncology from Buy to Neutral

    2/6/25 7:53:07 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    SEC Filings

    View All

    SEC Form S-8 filed by Kura Oncology Inc.

    S-8 - Kura Oncology, Inc. (0001422143) (Filer)

    6/4/26 5:25:23 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Kura Oncology, Inc. (0001422143) (Filer)

    6/4/26 4:05:17 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Kura Oncology Inc.

    DEFA14A - Kura Oncology, Inc. (0001422143) (Filer)

    5/26/26 4:38:11 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Wilson Troy Edward bought $410,145 worth of shares (50,000 units at $8.20), increasing direct ownership by 98% to 100,968 units (SEC Form 4)

    4 - Kura Oncology, Inc. (0001422143) (Issuer)

    9/9/25 4:28:40 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Financials

    Live finance-specific insights

    View All

    Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

    – Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients – – Clinical activity observed in both KRAS inhibitor-naïve and KRAS inhibitor-pretreated patients – – Preclinical data support broad applicability across the evolving RAS inhibitor landscape, including mutant-selective, pan-KRAS and RAS(ON) multi-selective inhibitors – – New platform study designed to accelerate evaluation of darlifarnib across multiple targeted therapies, combinations, and disease settings – – First planned platform combination, darlifarnib + da

    6/3/26 6:53:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

    – Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results reinforce darlifarnib's potential as a precision combination agent across targeted therapies – – Clear clinical activity in KRASi-experienced patients and manageable safety profile – – Virtual investor event on June 3, 2026, at 12:15 p.m. PT / 3:15 p.m. ET – SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today reported compelling first-in-human data fro

    5/26/26 6:02:00 AM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology Reports First Quarter 2026 Financial Results

    – $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and combination adoption, reflect strong early momentum – – Broad and rapid payer access achieved, with > 93% coverage and favorable positioning across > 12 million lives – – Multiple 2026 data readouts expected to support ziftomenib as a broadly combinable backbone across AML – – $580.8 million in cash, cash equivalents and short-term investments, plus $180 million in anticipated collaboration payments, expected to support advancement of ziftomenib AML program through first topline KOMET-017 Phase

    5/12/26 4:02:00 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Kura Oncology Inc.

    SC 13G - Kura Oncology, Inc. (0001422143) (Subject)

    12/5/24 6:55:37 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

    SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

    11/14/24 4:31:29 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

    SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

    11/14/24 4:32:22 PM ET
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KURA
    Leadership Updates

    Live Leadership Updates

    View All

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

    – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

    10/29/24 8:00:00 AM ET
    $AMAM
    $KURA
    $RNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations